Portfolio Companies 2026 for Access Biotechnology: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.
Access Biotechnology accounts for 18 tracked companies with verified cap-table data, 18 of which disclose round sizes totalling $4B. The median disclosed raise is $140M, and the largest is ACELYRIN at $758M, ahead of Spyre Therapeutics ($644M) and Hemab ($537M).
The names that recur most often on these portfolio cap tables are Access Biotechnology (18 companies), Atlas Venture (6 companies), OrbiMed (6 companies), RA Capital Management (3 companies), Sanofi Ventures (3 companies), VenBio Partners (2 companies). By latest disclosed round, the market skews Series B (6), Series A (6), Series C (3), Growth (2).
Companies tracked: 18
Disclosed funding total: $4B across 18 companies
Median disclosed raise: $140M
Largest raise: ACELYRIN — $758M
Stage mix: Series B 6 · Series A 6 · Series C 3 · Growth 2
